依达拉奉治疗急性脑梗死的临床观察

Efficacy of Edaravone Combined with Shuxuetong for Acute Cerebral Infarction

目的观察依达拉奉和疏血通联合治疗急性脑梗死的疗效和安全性。方法将入选患者随机分为依达拉奉治疗组(40例)和对照组(40例),对照组给予疏血通注射液及常规治疗,治疗组在此基础上加用依达拉奉注射液治疗,连续观察21 d,比较2组治疗前后的美国国立卫生研究院卒中量表(NIHSS)和Barthel指数(BI)评分,并监测血小板计数、血凝常规和肝肾功。结果2组治疗后NIHSS评分降低,BI评分升高。治疗后组间相比,治疗组在降低NIHSS评分和提高BI评分与对照组比均有统计学意义。依达拉奉和疏血通注射液在使用中无明显毒副作用。结论依达拉奉可显著降低NIHSS评分,提高BI评分,可促进神经功能恢复,为急性脑梗死的有效治疗用药。

Objective To investigate the effect and safety of Edaravone combined with Shuxuetong in the treatment of acute cerebral infarction （ACI）. Methods 80 cases with ACI received routine treatment and were randomly divided into two groups （n =40）, The treatment group was given Edaravone combined with Shuxuetong and the control group was merely given Shuxuetong for 21 days. National Institutes of Health Stroke Scale （NIHSS） and Barthel Index （BI） were measured before and after treatment respectively. The platelet count, coagulation studies, liver function and kidney function were also tested at the same time, Results The scores of the NIHSS decreased and the BI increased after treatment in both groups. There was statistical difference between the two groups. No adverse effects were found in the treatment by Edaravone combined with Shuxuetong. Conclusions Edaravone combined with Shuxuetong can obviously decrease the scores of NIHSS and increase the scores of BI and improve the nerve function. It is an effective medicine for acute cerebral infarction.